RxDoctor Payments Data

Peer Soderberg, MD

Family Medicine · Elbridge, NYNPI 1316926397

Payments from drug & device makers

$6,813in general payments, 2019–2025

Across 395 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$921
  • Novo Nordisk$875
  • AbbVie$807
  • Astellas Pharma US Inc$395
  • Merck$388
  • Pfizer$334
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,802100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,813 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$70,264
Medicare patients
320
Services billed
8,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$56,284
MounjaroTirzepatide27$29,677
JardianceEmpagliflozin28$28,376
TrulicityDulaglutide21$27,193
OzempicSemaglutide28$25,886
EliquisApixaban11$9,208
Repatha SyringeEvolocumab12$6,384
MyrbetriqMirabegron12$5,307
Levothyroxine Sodium80$3,280
Albuterol Sulfate HfaAlbuterol Sulfate81$2,404
Icosapent Ethyl13$1,757
Memantine Hcl ErMemantine Hcl18$1,505
Atorvastatin Calcium72$819
Rosuvastatin Calcium57$539
Desvenlafaxine Succinate ErDesvenlafaxine Succinate34$485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$921$56,87048 claims
GSKTrelegy Ellipta$294$56,28459 claims
Boehringer IngelheimJardiance$270$28,37628 claims
Novo NordiskOzempic$875$25,88628 claims
PfizerEliquis$334$9,20811 claims
Astellas Pharma US IncMyrbetriq$395$5,30712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$81$3,28080 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Elbridge

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →